Clinical Overview

Lichen planopilaris (LPP) represents a lymphocytic scarring alopecia characterized by chronic inflammation of the hair follicle upper portions, leading to permanent hair loss. The condition affects approximately 1-3% of alopecia patients globally, with higher prevalence in African, Hispanic, and Asian populations. LPP manifests as progressive hair loss in a patchy distribution, often accompanied by symptoms including burning, itching, and pain at affected scalp regions. The inflammatory process targets the follicular epithelium and sebaceous glands, causing their destruction and resulting in irreversible alopecia if not addressed therapeutically early in disease progression.

Pathophysiology and Etiology

Lichen planopilaris develops through T-lymphocyte-mediated autoimmune destruction of the hair follicle infundibulum and isthmus, paralleling the mechanisms observed in cutaneous lichen planus. Histopathological examination reveals dense lymphocytic infiltration in a "lichenoid" pattern around affected follicles, with preserved hair follicle bulbs distinguishing LPP from other scarring alopecias. The precise triggering mechanisms remain incompletely understood, though genetic susceptibility and potential environmental triggers including infections or trauma appear implicated in disease initiation. Approximately 15-30% of LPP patients demonstrate concurrent skin or mucosal lichen planus, suggesting shared autoimmune mechanisms. HLA-A3 and HLA-B7 alleles show associations with LPP susceptibility in certain populations.

Clinical Presentation and Diagnosis

Patients typically present with progressive scarring hair loss in irregular patches, most commonly affecting the crown and vertex. Early-stage lesions may present with erythematous, slightly raised peripilar inflammation with follicular hyperkeratosis creating a "perifollicular erythema" appearance. Active inflammation produces burning or pruritic sensations that may precede visible hair loss. The diagnosis is established through scalp biopsy demonstrating the characteristic lichenoid infiltrate surrounding follicles with preserved follicle bulbs. Dermoscopy reveals follicular hyperkeratosis, peripilar erythema, and characteristic follicle changes distinguishing LPP from androgenetic alopecia or other non-scarring conditions. Early biopsy during active inflammation stages optimizes diagnostic accuracy compared to advanced fibrotic disease where diagnostic features become less distinct.

Early-Stage versus Late-Stage Disease

Disease progression from inflammatory early stages to fibrotic late stages spans months to years, with significant implications for treatment responsiveness. Early-stage disease (active inflammation on histology) responds substantially better to anti-inflammatory therapies, with potential for halting progression and limiting permanent scarring. Late-stage disease characterized by follicle fibrosis and replacement with dermal fibrosis proves largely unresponsive to medical therapies, rendering early diagnosis and intervention critical for disease management. Patients should be counseled that delayed treatment significantly reduces probability of preserving remaining hair and improving overall outcomes.

Medical Management - First-Line Therapies

Topical corticosteroids and calcineurin inhibitors represent first-line therapies for early-stage LPP. Potent topical corticosteroids (fluocinonide 0.05% solution or cream) applied directly to affected areas 2-3 times daily reduce peripilar inflammation and delay disease progression. Topical tacrolimus (0.1% ointment) applied twice daily provides alternative for patients unable to tolerate prolonged systemic corticosteroid exposure or demonstrating steroid-responsive disease. Approximately 30-50% of patients with early-stage disease achieve disease stabilization or improvement with topical agents alone, though response rates decline significantly with disease duration and extent.

Systemic Therapeutic Approaches

Systemic therapies become necessary for progressive or refractory cases. Oral corticosteroids (prednisone 0.5-1 mg/kg daily initially, then tapered) combined with intralesional corticosteroid injections demonstrate superior efficacy compared to topical therapies alone, with 60-70% of patients achieving disease stabilization. Hydroxychloroquine (200-400 mg daily) demonstrates immunomodulatory effects reducing LPP inflammation in 40-50% of patients, though response development requires 2-3 months of treatment. Combination approaches integrating oral hydroxychloroquine with systemic corticosteroids and topical therapies show highest efficacy for disease control. Mycophenolate mofetil (1-3 g daily in divided doses) offers steroid-sparing alternative for patients developing corticosteroid dependence or demonstrating inadequate response to conventional therapies, with approximately 60% demonstrating clinical response.

Adjunctive and Emerging Treatments

Intralesional corticosteroid injections (triamcinolone acetonide 2.5-5 mg/mL) administered directly into active inflammatory lesions every 4-6 weeks provide potent local anti-inflammatory effects reducing peripilar erythema and potentially preserving marginal follicles. Minoxidil (5% topical twice daily) stimulates anagen entry in remaining follicles, providing modest cosmetic improvement though not addressing underlying inflammation. JAK inhibitors including ruxolitinib show promise in early-stage reports with approximately 40% of LPP patients demonstrating hair regrowth in preliminary data, though larger controlled studies remain pending. Low-level laser therapy and excimer laser (308-nm) demonstrate preliminary benefits in small cohorts but lack sufficient evidence for definitive recommendations.

Scarring Reversal and Surgical Options

Established permanent scarring in late-stage LPP proves unresponsive to medical therapies. Hair transplantation in stable patients with inactive disease and adequate donor hair supply may improve camouflage of scarred areas, though surgical intervention requires disease quiescence for minimum 12 months prior to transplantation. Scalp micropigmentation simulates hair density in scarred regions, providing cosmetic improvement though not addressing underlying alopecia. Patient counseling should address that advanced disease may progress to totality despite appropriate intervention, necessitating expectations management and psychosocial support.

Frequently Asked Questions

Is lichen planopilaris contagious? No, LPP is a non-contagious autoimmune condition. The inflammatory destruction of hair follicles cannot spread to others through contact.

Will I lose all my hair? Disease severity varies; some patients experience limited patchy hair loss while others develop extensive scarring alopecia. Early treatment significantly improves hair preservation prospects.

Can hair regrow in scarred areas? Established scarring produces permanent follicle destruction preventing regrowth. Early treatment during inflammatory stages may limit scar formation and preserve remaining hair.

What triggers lichen planopilaris? Precise triggering mechanisms remain incompletely understood; genetic susceptibility, infections, and trauma appear implicated. No clear preventive strategies are established.

References

  1. Kang H, Liao W. Lichen planopilaris, its variants and related conditions. Dermatologica Sinica. 2011;29(4):155-161.
  2. Samrao A, Chew S, Price V. Lichen planopilaris: epidemiology, pathogenesis, clinical presentation, and management. J Am Acad Dermatol. 2013;68(4):573-581.
  3. Assouly P, Reygagne P. Lichen planopilaris and frontal fibrosing alopecia: diagnosis and management. Dermatol Clin. 2013;31(1):131-142.
  4. Sotiropoulos VC, Wisniewski M, Kim SJ. Lichen planopilaris: clinical features and response to treatment. Dermatol Surg. 2011;37(5):592-599.
  5. Sears KS, Tan KS, Abrar QS, et al. An epidemiological analysis of lichen planopilaris in the United States. Cutis. 2015;96(3):209-214.
  6. Miteva M, Tosti A. Lichen planopilaris diagnosis and treatment. Semin Cutan Med Surg. 2009;28(1):3-10.
  7. Georgala S, Befon A, Georgala C, et al. Treatment of lichen planopilaris with intralesional corticosteroids. J Am Acad Dermatol. 2007;56(2):222-227.
  8. Chieregato C, Ferri R, Sardana K, et al. Hydroxychloroquine in lichen planopilaris: an open-label, nonrandomized study. Dermatology. 2010;221(2):171-174.
  9. Saceda-Corralo D, Moreno-Arrones OM, Alegre-Sanchez A, et al. Baricitinib in lichen planopilaris: clinical and dermoscopic long-term results. J Am Acad Dermatol. 2021;85(4):E33-E35.
  10. Steen WJ, Rosser MC, Ryu S, et al. Management of lichen planopilaris: current perspectives. Clin Cosmet Investig Dermatol. 2023;16:159-170.